Back to search results

Adaptive Radiation for Abdominopelvic Metastases

This study is testing a type of radiation therapy called Adaptive Stereotactic Body Radiation (SBRT) for people with cancer that has spread to their abdomen or pelvis. The goal is to see if this radiation can safely deliver higher doses to these areas without causing serious side effects. You might be able to join if you are 18 or older and have cancer that has spread to your abdomen or pelvis, and has not been treated with radiation or other local methods in that area. The study will look at how well the treatment works and if side effects are kept to a minimum, specifically checking for serious side effects at 3 months after treatment.

Study design
This is a single-arm Phase 1 study, meaning all 30 participants will receive the Adaptive Stereotactic Body Radiation. It is designed to find the best dose of radiation to use in future studies.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goal of the study is measured at 3 months after treatment to check for side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05880667

Adaptive Radiation for Abdominopelvic Metastases

Recruiting
PHASE1Ages 18+InterventionalTreatment
Fox Chase Cancer Center
~30 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:Adaptive Stereotactic Body Radiation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.
Measured over 3 months

Conditions

Neoplasm - Soft Tissue Pelvis Malignant Secondary
Malignant Neoplasm of Stomach

Explore related trials

Gastric CarcinomaSoft Tissue SarcomaSolid Neoplasm

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Joshua Meyer, MD · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center

Who to contact

Tanu Singh
[email protected]
12152141439
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute neutrophil count \> 1,500/mcL
Platelets \> 100,000/mcL
Total bilirubin \< 2 mg/dL
AST/ALT (SGOT/SGPT) \< 5X ULN
Creatinine \< 1.5X ULN OR
Creatinine clearance ≥ 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal 6. Subjects must possess the ability to understand and willingness to sign a written informed consent and HIPAA consent document. Translation services including translation of informed consent documents will be provided, as feasible, to encourage diversity of inclusion of eligible patients.

What this trial measures

  • To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.3 months

    Cohorts of size 10 will be enrolled, Severe (grade 3) toxicity occurring within 3 months of treatment that is possibly, probably, or definitely related to trial therapy will be assessed.